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ABSTRACT 
Background: Cerebral autosomal dominant arteriopathy with subcortical infarcts and 
leukoencephalopathy (CADASIL) is the most common familial cerebral small vessel disease, 
caused by NOTCH3 gene mutations. The aim of our study was to identify clinical and 
neuroradiological features which would be useful in identifying which patients presenting with 
lacunar stroke and TIA are likely to have CADASIL. Methods: Patients with lacunar stroke or TIA, 
were included in the present study. For each patient demographic and clinical data were collected. 
MRI images were centrally analysed for the presence of lacunar infarcts, microbleeds, temporal 
lobe involvement, global atrophy and white matter hyperintensities. Results: 128 patients (mean age 
56.3±12.4 years) were included. A NOTCH3 mutation was found in 12.5% of them. A family 
history of stroke, the presence of dementia and external capsule lesions on MRI were the only 
features significantly associated with the diagnosis of CADASIL. Although thalamic, temporal pole 
gliosis and severe white matter hyperintensities were less specific for CADASIL diagnosis, the 
combination of all these factors together with familial history for stroke result in a higher positive 
predictive value and specificity. Conclusions: A careful familial history collection and 
neuroradiological assessment can identify patients in whom NOTCH3 genetic testing has a higher 
yield. 
 
Key words: CADASIL, NOTCH3 gene, stroke genetics, diagnosis, neuroimaging, monogenic 
disorders 
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INTRODUCTION 
CADASIL (Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and 
Leucoencephalopathy; OMIM#125310) is the most common cause of familial cerebral small 
vessels disease. [1].  It usually manifests at middle adulthood with a highly variable clinical 
phenotype including recurrent TIA or ischemic stroke, migraine with aura, cognitive deficits and 
mood disorders [2,3]. T2-White matter hypertensities (WMHs), with involvement of the external 
capsules and anterior pole of the temporal lobes and multiple lacunar infarcts have been identified 
as typical CADASIL neuroimaging findings [4,5]. The disease is due to mutations in the NOTCH3 
gene, occurring in exons 2–24 [6], which encode for epidermal growth factor (EGF)-like repeats [7]. 
The extremely variable phenotype makes determining which patients presenting with 
lacunar stroke or small vessel disease should be screened for CADASIL challenging [8-9]. Hence, 
the identification of reliable clinical and neuroimaging screening criteria would be useful as 
NOTCH3 genetic analysis is costly and time consuming [9]. 
The aim of the present study was to determine which patients presenting with lacunar stroke and 
TIA are likely to have a diagnosis of CADASIL and to identify clinical and neuroradiological 
features which could be used as possible markers to decide which patient to refer for genetic 
screening.  
 
PATIENTS AND METHODS 
Patients 
We included a series of consecutive patients with lacunar ischemic and/or TIA and/or deep 
intracerebral heamhorrage (basal ganglia) who had been prospectively recruited from the 18 stroke 
services participating in the Lombardia GeNetics of Stroke (GENS) project (2009-2016) who had 
undergone sequencing of the NOTCH3 gene [10-11; Supplemental data 1]. 
Recruited patients met inclusion criteria suggesting a high likelihood of familial small vessel 
disease.  
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A specific clinical algorithm was implemented based on a literature review to identify patients with 
a higher probability of CADASIL (Figure 1) [12,13]. One (1) point score was attributed to every 
single item (total sum ranging from 0 to 6), and patients with a > 2 score were included in the study 
and addressed to genetic analysis. The full study methodology has been previously reported [10-
11]. 
On a standard pro-forma demographic, clinical and risk factor data were collected as well as 
specific clinical features commonly associated with CADASIL, including history of recurrent 
strokes/TIA, migraine with or without aura, dementia, cognitive impairment, and the presence of 
family history of stroke, psychiatric disturbance, and seizure [11; Supplemental data 2].  
The study was approved by the local ethical committees of all participating centres, in 
accordance with the ethical standards of the 1964 Declaration of Helsinki and its later amendments. 
All the subjects gave informed consent for genetic testing and participation in the study. 
 
Neuroimaging analysis 
All participants underwent 1.5T MRI scans which included DWI, FLAIR and T2*gradient-
echo in axial planes, and T2 (+-PD) in axial or coronal plans. MRIs acquired in the different centres 
were centrally evaluated by a neuroradiologist with long-term experience in small vessel disease 
imaging (P.V.; IRCCS C. Mondino National Neurological Institute, Pavia, Italy). Visual assessment 
was performed blinded to clinical and demographic data as well as genetic analysis results. The 
STandards for ReportIng Vascular changes on Neuroimaging (STRIVE) guidelines, recognising 
standards developed by rigorous expert consensus, were applied to assess multifocal vascular 
lesions [14].  The ratings included the presence and site of lacunar infarcts, the presence of 
microbleeds, the overall severity of white matter hyperintensities (WMHs) according to the 
simplified Fazekas scale (range: 0-3), and the presence and the degree of WMH in the anterior 
temporal poles and external capsule [15].  The global atrophy and medial temporal lobe atrophy 
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were rated by applying the Pasquier scale (range: 0-3) [16]   and the Scheltens scale (range: 0-4) 
[17], respectively (Figure 2). 
Genetic analysis 
Blood samples for DNA analysis were collected, after informed consent. Total genomic 
DNA was extracted from peripheral blood leukocytes. Sequencing of all exons of the NOTCH3 
gene encoding for the epidermal growth factor (EGF)-like repeats in which pathogenic CADASIL 
mutations occur was performed on an automated sequencing system (Applied Biosystems 3730 
DNA Analyzer) using the BigDye™ Terminator Cycle Sequencing Kit Version 1.1 (Applied 
Biosystems). The nucleotide position of mutation present in the coding regions refers to the mRNA 
sequence (NM_000435). 
Statistical analysis 
Given the small subgroups sample size, Fisher exact test was applied for categorical 
variables to evaluate associations between genetic results and algorithm variables, and differences 
in clinical and neuroimaging features between NOTCH3 gene positive and negative patients. Non-
parametric Kruskal-Wallis test was applied to evaluate associations between genetic results and 
continuous variables. Two separate multiple logistic regression analysis models (Firth method) 
adjusted for age at disease onset and sex were applied to assess the independence of single 
predictive clinical and neuroradiological factors, respectively, which had been found to be 
significant on univariate analysis. Genetic test result was used as dependent variable for each of 
single feature.  
The accuracy of each variable or combination of them in predicting genetic diagnosis was expressed 
using the area under curve of the Receiver Operating Characteristic (ROC-AUC).  
Tests were considered significant if the p value was less than 0.05. All analyses were 
calculated using STATA 8.0 (StataCorp LP, College Station, Texas, US). 
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RESULTS 
A total of 128 patients with a suspicion of CADASIL were recruited. Disease age of onset 
was 55 ± 13.2 years, and 64 (50%) were females. The presenting symptom was stroke in 83 
(64.8%) cases, which was ischemic in 89% and haemorrhagic in 11% of subjects and TIA in 45 
(35.2%) patients. 
Genetic analysis revealed NOTCH3 gene mutations in 16 (12.5%) of the patients. All 
mutations were already described missense changes, abolishing or introducing a cysteine residue. 
Details of mutation site and phenotype of positive NOTCH3 patients are reported in Table 1. 
Clinical and risk factors differences between NOTCH3 positive and negative cases are 
shown in Table 2. Family history of stroke (93.7% vs. 47.3%, p=0.003) and dementia (43.7% vs. 
16.9%, p=0.021) were the only significant clinical features differentiating NOTCH3 positive from 
negative patients.  
Cerebral MRI scans were available for central assessment in 101 (78.9%) subjects. 
Neuroimaging analysis (Table 3) showed that both the presence and the number of thalamic (92.8% 
vs. 49.4%%; p=0.003; 1.92±2.09 vs. 066±0.56; p=0.002, respectively) and external capsule lacunes 
(92.8% vs. 50.5%; p=0.003; 0.93±.27; p=0.003) were significantly associated with a CADASIL 
diagnosis. Temporal lobe white matter hyperintensities (50% vs. 17.2%; p=0.012) and WMHs 
(Fazekas 3 = 64.2% vs. 29.8%%; p=0.031) were also significantly more frequent in NOTCH3 
positive than negative patients. No other neuroradiological feature, including temporo-mesial and 
global cortical atrophy, was associated with CADASIL.  
Multiple logistic regression analysis corrected for age at onset and sex with genetic test as 
the dependent variable, confirmed the association between family history of stroke (OR 6.27; 
95%CI 1.33-29.40; p=0.020) and of dementia (OR 3.19;95%CI 1.00-10.17; p=0.050) and external 
capsule lacunes (OR 10.99; 95%CI 1.06-114.4; p=0.045) with the positive genetic test 
(Supplemental table – Supplemental data 3). 
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The ROC-AUC curve analysis showed that the predictive diagnostic accuracy was 
significantly improved by using a combination of multiple factors. The AUC was 0.6728 (95%CI 
0.56-0.78) and 0.7085 (95%CI 0.63-0.79) for a family history of stroke and capsule external lacunes 
alone respectively, whereas increases to 0.826 (95%CI 0.69-0.96) when these factors are combined 
together and with the presence thalamic lacunes, temporal lobe WMH and severe WMHs (Fazekas 
grade 3) (Figure 3). 
 
DISCUSSION 
We developed a new pre-genetic algorithm to select patients with cerebrovascular diseases 
in whom there is a yield sufficient to merit testing [10-11].  The application of this clinical 
algorithm allowed the selection of a patient population highly suspected for CADASIL, which was 
genetically confirmed in a relatively high proportion of cases (12.5%). 
There have been some previous attempts of identifying specific clinical and 
neuroradiological features distinguishing NOTCH3 positive from negative patients. These studies, 
showed that several MRI characteristics, such as temporal lobe lesions, external capsule lacunes, 
severe WMHs as well as the family history, were more frequent in positive patients [9,18-22].  
Some specific algorithms supporting the identification of clinically suspected CADASIL have been 
proposed so far but the reliability is still debated since in most cases they were elaborated from 
heterogeneous and retrospectively collected populations [12-22].  A recent systematic screening of 
994 lacunar stroke subjects with stroke onset by age 70 years detected CADASIL mutations in only 
0.5-1.5% of the patients [18] making the use of better screening strategies, as we have developed in 
this analysis, clinically important. 
Although the strength of our study is that the screening strategy was firstly applied in a 
prospectively collected and well phenotyped series of lacunar stroke or TIA patients, some possible 
limitations of our work should be highlighted. Firstly, the study was conducted on a relative small 
sample size and the algorithm has not been validated by systematically performing the genetic tests 
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in a pool of randomly selected stroke cases [11].   Thus, the reliability of our algorithm should be 
assessed on wider series. Secondly, our algorithm has been developed from international literature, 
[12,13]  and not from a systematic statistical analysis.  
Our study may provide clinically useful information in the selection of patients presenting with 
lacunar stroke for CADASIL mutation testing. We confirmed that a family history of stroke and 
dementia as well as the presence of external capsule lacunes are strongly associated with a 
diagnosis of CADASIL. [9,11,23-25].  Conversely, we found that the presence of severe WMHs, 
thalamic lacunes, and temporal lobe WMHs may be less useful. However, since the combination of 
the overall factors together with familial history for stroke likely result in higher positive predictive 
values and specificity, these neuroradiological aspects should be considered to identify patients 
yield of genetic testing. 
We did not find any correlation between diagnosis of CADASIL and temporo-mesial and 
cortical atrophy This finding, may reflect the subcortical nature of the disease or may be explained 
by the relative small proportion of patients with cognitive impairment in the NOTCH3 positive 
patients (43.7% versus 27.5%) or by the relative short patient disease history (mean 1 year). In fact, 
a relationship between brain atrophy, clinical severity and cognitive decline has been observed, and 
age was found as the main risk factor for longitudinal brain volume loss [26-29].   
Our results support the idea that the application of a pre-genetic screening selection taking 
into consideration both familial and neuroradiological data is likely to represent a promising 
strategy for CADASIL diagnosis.  
However, the increasing application of rapid and cost effective high-throughput technologies 
such as Next generation sequencing in monogenic diseases will have a major impact in CADASIL 
diagnosis by assessing whether a systematic genetic screening is preferable to a clinical pre-genetic 
screening approach. 
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FIGURE LEGEND 
 
Figure 1. The Lombardia GENS Algorithm. 
 
Figure 2.  Neuroradiological Items evaluated 
 
Figure 3. ROC curves of different variable combination in relation to the genetic diagnosis of 
CADASIL. Line 1: familial history of stroke; Line 2: familial history of dementia; Line 3: thalamic 
lacunes; Line 4: external capsule lacunes; Line 5: temporal lobe white matter hyperitensities; Line 
6: familial history of stroke and temporal lobe white matter hyperintensities; Line 7: familial history 
of stroke and external capsule lacunes; Line 8: familial history of stroke, temporal pole 
hyperitensithies and external capsule lacunes; Line 9: familial history of stroke, temporal pole 
hyperintensities,  external capsule lacunes and severe white matter hyperintensities (Fazekas 3). 
 
 
 
 
 
